XENE 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
價值面評分中等,已經有部位可以持續持有,若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
XENE 近期報酬表現
-1.02%
Xenon pharmaceuticals inc
1.96%
同產業平均
0.51%
S&P500
與 XENE 同產業的標的表現
股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
---|---|---|---|---|---|---|---|
VYGR | Voyager therapeutics inc | 4 分 | 4 分 | 4 分 | 2 分 | 1 分 | |
MLYS | Mineralys therapeutics inc | - | 4 分 | 2 分 | 2 分 | 1 分 | |
LXEO | Lexeo therapeutics inc | - | 3 分 | 3 分 | 3 分 | 1 分 | |
CRGX | Cargo therapeutics inc | - | 2 分 | 2 分 | 3 分 | 1 分 | |
MRUS | Merus nv | 4 分 | 5 分 | 5 分 | 3 分 | 1 分 |
- VYGR Voyager therapeutics inc價值 4 分趨勢 4 分波段 4 分籌碼 2 分股利 1 分查看更多
XENE 公司資訊
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company's product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).